Rare diseases specialist Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said the French authorities have signed off its drug Myalepta for reimbursement.
The Ministry of Social Affairs and Health said it will pay for the use of the treatment as an adjunct to diet for those with leptin deficiency with congenital or acquired general lipodystrophy (abnormal fat distribution in the body).
“Today’s news represents further progress in our efforts to grow the geographic reach of our commercial products in both existing and new territories,” said chief executive, Dr Joe Wiley.